ArticleCancers2026

Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.

Teiji Kuzuya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.